

Division of Internal Medicine Faculty Papers & Presentations

Division of Internal Medicine

6-5-2010

Pulmonary Hypertension Is a Frequent Event in Patients with Chronic Myeloid Leukemia Treated with Tyrosine Kinase Inhibitors

Sameh Gaballa Thomas Jefferson University

Aref Al-Kali The University of Texas M.D. Anderson Cancer Center

Hagop Kantarjian The University of Texas M.D. Anderson Cancer Center

Elias Jabbour The University of Texas M.D. Anderson Cancer Center

Alfonso Quintas-Cardama Follow this and additional works at: https://idc.jefferson.edu/internalfp

Part of the Oncology Commons

Let us know how access to this document benefits you

Recommended Citation

Gaballa, Sameh; Al-Kali, Aref; Kantarjian, Hagop; Jabbour, Elias; Quintas-Cardama, Alfonso; Ayoubi, Mohamad; Borthakur, Gautam; O'Brien, S. M.; and Cortes, J. E., "Pulmonary Hypertension Is a Frequent Event in Patients with Chronic Myeloid Leukemia Treated with Tyrosine Kinase Inhibitors" (2010). *Division of Internal Medicine Faculty Papers & Presentations.* Paper 5. https://jdc.jefferson.edu/internalfp/5

This Article is brought to you for free and open access by the Jefferson Digital Commons. The Jefferson Digital Commons is a service of Thomas Jefferson University's Center for Teaching and Learning (CTL). The Commons is a showcase for Jefferson books and journals, peer-reviewed scholarly publications, unique historical collections from the University archives, and teaching tools. The Jefferson Digital Commons allows researchers and interested readers anywhere in the world to learn about and keep up to date with Jefferson scholarship. This article has been accepted for inclusion in Division of Internal Medicine Faculty Papers & Presentations by an authorized administrator of the Jefferson Digital Commons. For more information, please contact: JeffersonDigitalCommons@jefferson.edu.

Authors

Sameh Gaballa, Aref Al-Kali, Hagop Kantarjian, Elias Jabbour, Alfonso Quintas-Cardama, Mohamad Ayoubi, Gautam Borthakur, S. M. O'Brien, and J. E. Cortes

Pulmonary Hypertension Is a Frequent Event in Patients with Chronic Myeloid Leukemia Treated with Tyrosine **Kinase Inhibitors**

Sameh Gaballa¹, Aref Al-Kali², Hagop Kantarjian², Elias Jabbour², Alfonso Quintas-Cardama², Mohamad Ayoubi², Gautam Borthakur², S. M. O'Brien², J. E. Cortes² Department of Internal Medicine, Thomas Jefferson University, Philadelphia, PA and ² Department of Leukemia, The University of Texas M.D. Anderson Cancer Center, Houston, TX.

Dasatinib n=2, Imatinib n=2, Nilotinib n= 3)

normalized after starting therapy with nilotinib.

· Pleural effusion occurred most frequently among

Median (range) N° (%)

56 (30-82)

16 (2-54)

27.2 (2.7-

156.5)

228 (70-599)

12.2 (6.2-14.1)

Table 1. Patient's Characteristics

High

Low

Intermediate

Pleural effusion during TKI

Systemic Hypertension

Coronary artery disease

Obstructive sleep Apnea

Diastolic heart failure

Systolic heart failure

Tobacco smoking

Atrial Fibrillation

COPD

dose of dasatinib by 50% (N=1).

with elevated RVSP (Table 3)

patients on dasatinib (70%).

Median follow-up (months)

Median WBC (x10⁹/L)

Platelets (x109/L)

Hemoalobin (a/dl)

Splenomegaly

Medical History

Sokal score

Results

(figure 1).

Age (v)

Males

MDAnderson Cancer Center

PH occurs in some patients with CML in

appears during therapy with TKI

chronic phase at baseline while in others it

PH is seen less commonly in patients on

Concomitant pleural effusion and PH

occurred more frequently in patients

Unclear whether there is a causal

relationship between TKI and PH.

TKIs and the development of PH.

• A larger prospective study is needed to

further investigate the relationship between

Unexplained pulmonary hypertension in c myeloproliferative disorders. Chest 2001;120:801-8.

pulmonary hypertension secondary to dasatinib in a

patient with chronic myeloid leukemia. Leuk Res

arterial hypertension and right ventricle failure in a previously allografted CML patient. Bone Marrow

Quintas-Cardama A, Kantarjian H, O'Brien S, et al. Pleural

treated with dasatinib after imatinib failure. J Clin Onco

effusion in patients with chronic myelogenous leuk

imatinib compared to dasatinib or nilotinib.

Conclusions

receiving dasatinib

References:

2009:33:861-4

2007:25:3908-14

Transplant 2009;43:967-8.

Abstract

Background: Tyrosine kinase inhibitors (TKI) are the current dard therapy for patients with chronic myeloid leukemia (CML). Fluid retention and pleural effusions have been reported patients treated with TKIs, particularly with dasatinib. Although TKIs have been shown to reverse pulmonary hypertension (PH) in animal models, there have been some reports of development of reversible PH with dasatinib. **Methods:** We conducted a or reversible PH with dasatilities Methods: we conculate a retrospective analysis on 401 patients diagnosed with CML in chronic phase (CP) who were treated with TKIs (imalinib, dasatinib, on initial therapy for LML and had a transfloracic echocardiogram (TTE) done at some point during the course of therapy. FH was diagnosed if the patient had an estimated right ventricular systolic pressure (RVSP) of 35 mm Hg or greater. Secondary causes of PH (systolic or diastolic dystunction on TTE, chronic obstructive pulmonary diseases [COPD], obstructive sleep apnea [OSA] and pulmonary embolism) were investigated during chart review. Results: Twenty (23%) out of 87 patients had evidence of PH by TTE; Iventhy (23%) Out of 87 patients had exidence of PH by TE: median age 57 years, with 46% being males. Six pts (30%) received nilotinib 400mg twice daily, 4 (20%) patients had imathinib (400mg, n=1, 600mg, n=1 and 800mg daily, n=2), and 10 (50%) patients received dasatinib (dose varied 40-140mg daily). Five (25%) patients had coronary artery disease, 9 (45%) had systemic hypertension, 2 (10%) had COPD and 3 (15%) had systemic hypertension, 2 (10%) had COPU and 3 (15%) had OSA. Thirteen pis had serial TTE to compare the progression of PH including 6 (7%) who had a TTE prior to starting TKI. Among these 13 pte with serial TTE. Thad rising RVASP with one patient having mild global hypokinesia, another with diastolic dysfunction and another with OSA. Four of those 7 patients had normal RVSP on their TTE prior to starting therapy. Six other pts had RVSP on ther II is prior to starting therapy. Six other pts had improvement in the RVSP on senial TTE, 4 of them with systemic hypertension. Two of those 6 patients had elevated RVSP on their TTE prior to slarting therapy, one pt had no change. Eleven patients had pleural effusions (7 dasatinb, 3 imatinb, 1 inloitnb) associated with PH. Conclusions: TKI therapy is occasionally associated with thevelopment of PH, but RVSP may improve spontaneously in some patients. A prospective study is needed to further investigate the relationship between TKIs and the development of PH.

Background

- · Pulmonary hypertension (PH) is characterized by elevated pulmonary artery pressure, right ventricular hypertrophy and, eventually, right ventricular failure.
- · Unexplained PH has been described in some myeloproliferative disorders however evidence is lacking in patients with CML
- There have been some reports on the occurrence of reversible PH after treatment with dasatinib2, 3.

Objectives

· To investigate the frequency and characteristics of PH in patients with CML receiving therapy with tyrosine kinase inhibitors (TKIs).

Patients and Methods

- Chart review of patients with CML treated with TKIs at MDACC between 2000 and 2009.
- Included patients with CML in chronic phase (CP) enrolled in several studies using imatinib (800 mg orally daily), nilotinib (400 mg BID) or dasatinib (100mg orally daily) as frontline therapy who had at least one trans-thoracic echocardiogram (TTE) done at baseline or during the course of therapy.
- · Patients with CML CP who had received prior therapies were excluded

Results

- · Of 401 patients with CML treated with TKI as initial therapy, 87 had at least one TTE done
- Among 28 patients with pre-therapy (baseline) TTE, 8 (29%) patients had an elevated right ventricular systolic pressure (RVSP) at haseline
- Elevated RVSP suggesting pulmonary hypertension during therapy occurred in 20 (23%) of 87 patients
- · Elevated RVSP was seen most commonly in patients treated with dasatinib (occurring in 10 of 19 patients (53%)) [mean 36 mmHq, range 35-50 mmHgl and nilotinib (seen on 6 of 14 patients [43%]) [mean 36 mmHq, range 31-50 mmHg1 (Table 2)
- LVEF remained normal in 18 (90%) of the 20 patients with elevated RVSP, suggesting that PH could possibly be related to the use of TKIs.

70% of patients with elevated RVSP while on therapy with dasatinib had evidence of concomitant pleural effusions.

- Only 4 of 54 (8%) patients treated with imatinib had evidence of elevated RVSP (2 had other possible etiologies).
 - WBC= White blood cell, COPD= Chronic Obstructive Pulmonary Disease., y=

Figure 1. Algorithm of Patients with elevated RVSP who had serial TTE · Of the patients that had elevated RVSP (suggesting




Table 2. TTE evidence of PH by

tics	therapy			
N° (%)	ткі	N	N	N
		TTE	Elevated	Possible
11 (55)		Available	RVSP on	secondary
17 (51)			TTE (%)	cause of elevated RVSP
	lmatinib	54	4 (8)	2 had ischemic CAD with
2 (10)				low EF that worsened
3 (15)				after starting
5 (25)				TKI
12 (60)				
11 (55) 9 (45)	Dasatinib	19	10 (53)	2 had COPD, 1 had OSA
8 (40) 5 (25)	Nilotinib	14	6 (43)	2 had OSA
4 (20)				(with normal
3 (15)				RVSP prior
3 (15)				to starting
2 (10)				TKI)
2 (10)	TKI, tyrosine kinase inhibitor; TTT, transthoracic echocardiogram; RVSP,			
Discourse	right ventricle systolic pressure: CAD, coronary artery disease: EE election			

right ventricle systolic pressure; CAD, coronary artery d fraction: COPD, chronic obstructive pulmonary disease.

Table 3. Incidence of pleural

1. Dingli D, Utz JP, Krowka MJ, Oberg AL, Tefferi A. offusion N 2. Rasheed W, Flaim B, Seymour JF. Reversible severe Concomitant N TKI used of patients PE and with SOB elevated 3. Mattei D, Feola M, Orzan F, Mordini N, Rapezzi D, Gallamini A. Reversible dasatinib-induced pulmonary RVSP 3 of 4 (75%) 1 Imatinib Dasatinib 7 of 10 (70%) 4 Nilotinih 1 of 6 (17%) 0 **Contact Details:** TKI, tyrosine kinase inhibitor; RSVP, right ventricle systolic ssure, PE= Pleural Effusion

Disclosures HK & JC received

chronic

Jorge Cortes, M.D. Department of Leukemia research support University of Texas M D from BMS and Anderson Cancer Center 1515 Holcombe Blvd, Unit 428 Novartis Houston, TX 77030 (713) 794-5783 - phone (713) 794-4297 - fax E-mail: icortes@mdanderson.org